Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy

In this analysis, we compared costs and explored the cost-effectiveness of subsequent-line treatment with cetuximab or panitumumab in patients with wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) after previous chemotherapy treatment failure. Data were used from ASPECCT (A Study of Panit...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Clinical therapeutics Ročník 38; číslo 6; s. 1376 - 1391
Hlavní autori:	Graham, Christopher N., Maglinte, Gregory A., Schwartzberg, Lee S., Price, Timothy J., Knox, Hediyyih N., Hechmati, Guy, Hjelmgren, Jonas, Barber, Beth, Fakih, Marwan G.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 01.06.2016 Elsevier Limited
Predmet:	Adult Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Cancer therapies cetuximab Cetuximab - economics Cetuximab - therapeutic use Chemotherapy Clinical trials Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Cost analysis Cost-Benefit Analysis cost-effectiveness cost-minimization Disease-Free Survival Epidermal growth factor Exons Humans Internal Medicine Medical Education Metastasis Mutation Neoplasm Metastasis Panitumumab Patients Proto-Oncogene Proteins p21(ras) - genetics Quality of life Quality-Adjusted Life Years subsequent-line United States > US cost-effectiveness cetuximab cost-minimization colorectal cancer panitumumab subsequent-line
ISSN:	0149-2918, 1879-114X, 1879-114X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!